Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00177372
Other study ID # Pittirb0409119
Secondary ID
Status Completed
Phase Phase 4
First received September 12, 2005
Last updated January 28, 2016
Start date January 2005
Est. completion date September 2005

Study information

Verified date January 2016
Source University of Pittsburgh
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

This is a pilot clinical trial to evaluate whether the medical management of early pregnancy failure with mifepristone and misoprostol is an effective and acceptable treatment. Subjects with early pregnancy failure receive mifepristone followed 24 hours later by vaginal misoprostol for medical management. Subjects then return on study day 3 for a repeat ultrasound to assess passage of pregnancy tissue. subjects who still have a gestational sac present at Day 3 receive a second dose of vaginal misoprostol. All subjects have a follow-up at Day 15, by phone for those who passed the pregnancy with the first dose of misoprostol, and in person for those who received a second dose. Questionnaires are administered at the beginning and end of the study to determine acceptability.


Recruitment information / eligibility

Status Completed
Enrollment 30
Est. completion date September 2005
Est. primary completion date September 2005
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria: healthy hemodynamically stable females with a non-viable pregnancy

Exclusion Criteria:

- orthostatic hypotension, contraindication to either mifepristone or misoprostol, treatment during current pregnancy to provide surgical or medical evacuation of the uterus, evidence of ovarian hyperstimulation syndrome, known or suspected pelvic infection,known or suspected clotting defect or receiving anticoagulants, cardiovascular disease, current breastfeeding, pregnancy with and IUD in situ, current participation in another clinical trial, prior participation in this trial, suspected or confirmed endometrial AV malformation, clinical indication requiring the karyotyping of products of conception

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Intervention

Drug:
mifepristone/misoprostol
mifepristone 200 mg followed 24 hours later by misoprostol 800 mcg vaginally

Locations

Country Name City State
United States Magee-Womens Hospital Pittsburgh Pennsylvania

Sponsors (1)

Lead Sponsor Collaborator
University of Pittsburgh

Country where clinical trial is conducted

United States, 

References & Publications (1)

Schreiber CA, Creinin MD, Reeves MF, Harwood BJ. Mifepristone and misoprostol for the treatment of early pregnancy failure: a pilot clinical trial. Contraception. 2006 Dec;74(6):458-62. Epub 2006 Sep 7. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary to determine if medical management with mifepristone and misoprostol for early pregnancy failure is an effective and acceptable treatment 1-2 weeks No
Secondary to evaluate if the treatment of early pregnancy failure with mifepristone and misoprostol is as effective as induced abortion with these medications 1-2 weeks No
Secondary to assess if mifepristone/misoprostol treatment is acceptable to patients with early pregnancy failure 1-2 weeks No
Secondary to assess the predictors/indicators for successful mifpristone/misoprostol treatment in patients with early pregnancy failure 1-2 weeks No
See also
  Status Clinical Trial Phase
Completed NCT05216952 - Ulipristal Acetate for Use in Early Pregnancy Loss Phase 2
Completed NCT05198050 - Letrozole in Induction of Abortion of Anembryonic Pregnancy N/A
Terminated NCT00468299 - MiMi: A Randomized Trial of Mifepristone and Misoprostol for Treatment of Early Pregnancy Failure N/A